446 related articles for article (PubMed ID: 32376597)
1. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series.
Aouba A; Baldolli A; Geffray L; Verdon R; Bergot E; Martin-Silva N; Justet A
Ann Rheum Dis; 2020 Oct; 79(10):1381-1382. PubMed ID: 32376597
[No Abstract] [Full Text] [Related]
2. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L; ;
Ann Rheum Dis; 2020 Oct; 79(10):1277-1285. PubMed ID: 32620597
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
Mégarbane B; Scherrmann JM
J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
[No Abstract] [Full Text] [Related]
4. Reactivation of COVID-19 pneumonia: A report of two cases.
Ravioli S; Ochsner H; Lindner G
J Infect; 2020 Aug; 81(2):e72-e73. PubMed ID: 32389787
[No Abstract] [Full Text] [Related]
5. A case of COVID-19 infection presenting with a seizure following severe brain edema.
Kadono Y; Nakamura Y; Ogawa Y; Yamamoto S; Kajikawa R; Nakajima Y; Matsumoto M; Kishima H
Seizure; 2020 Aug; 80():53-55. PubMed ID: 32540636
[No Abstract] [Full Text] [Related]
6. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit.
Bessière F; Roccia H; Delinière A; Charrière R; Chevalier P; Argaud L; Cour M
JAMA Cardiol; 2020 Sep; 5(9):1067-1069. PubMed ID: 32936266
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of the initial patients hospitalized for COVID-19: a single-center report.
Medetalibeyoğlu A; Şenkal N; Çapar G; Köse M; Tükek T
Turk J Med Sci; 2020 Aug; 50(5):1436-1439. PubMed ID: 32490641
[No Abstract] [Full Text] [Related]
9. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time.
Davido B; Boussaid G; Vaugier I; Lansaman T; Bouchand F; Lawrence C; Alvarez JC; Moine P; Perronne V; Barbot F; Saleh-Mghir A; Perronne C; Annane D; De Truchis P;
Int J Antimicrob Agents; 2020 Oct; 56(4):106129. PubMed ID: 32755653
[TBL] [Abstract][Full Text] [Related]
10. Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?
Gemcioglu E; Davutoglu M; Ozdemir EE; Erden A
Mult Scler Relat Disord; 2020 Jul; 42():102196. PubMed ID: 32480326
[TBL] [Abstract][Full Text] [Related]
11. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Fujii H; Tsuji T; Yuba T; Tanaka S; Suga Y; Matsuyama A; Omura A; Shiotsu S; Takumi C; Ono S; Horiguchi M; Hiraoka N
Clin Rheumatol; 2020 Nov; 39(11):3171-3175. PubMed ID: 32844364
[TBL] [Abstract][Full Text] [Related]
12. Use of anakinra in severe COVID-19: A case report.
Filocamo G; Mangioni D; Tagliabue P; Aliberti S; Costantino G; Minoia F; Bandera A
Int J Infect Dis; 2020 Jul; 96():607-609. PubMed ID: 32437934
[TBL] [Abstract][Full Text] [Related]
13. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
14. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
Bilia S; Giannini D; Rizzelli GML; Tavoni A
Clin Exp Rheumatol; 2020; 38(3):579. PubMed ID: 32456767
[No Abstract] [Full Text] [Related]
15. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.
Okour M; Al-Kofahi M; Austin D
J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664
[No Abstract] [Full Text] [Related]
16. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Bartiromo M; Borchi B; Botta A; Bagalà A; Lugli G; Tilli M; Cavallo A; Xhaferi B; Cutruzzulà R; Vaglio A; Bresci S; Larti A; Bartoloni A; Cirami C
Transpl Infect Dis; 2020 Aug; 22(4):e13286. PubMed ID: 32279418
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-Induced Bacterial Endocarditis in COVID-19 Pneumonia - Something to Be Concerned About?
Regazzoni V; Loffi M; Garini A; Danzi GB
Circ J; 2020 Sep; 84(10):1887. PubMed ID: 32779609
[No Abstract] [Full Text] [Related]
18. Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID-19.
Valente-Acosta B; Moreno-Sanchez F; Fueyo-Rodriguez O; Palomar-Lever A
BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32587121
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
[TBL] [Abstract][Full Text] [Related]
20. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
